Skip to main content

Advertisement

SpringerLink
Log in

Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227: comparison to FDG–PET

  • Original Communication
  • Published:
Journal of Neurology Aims and scope Submit manuscript

Abstract

We recently developed a novel PET tracer, 11C-labeled 2-(2-[2-dimethylaminothiazol-5-yl]ethenyl)-6-(2-[fluoro]ethoxy)benzoxazole ([11C]BF-227), and had success with in vivo detection of amyloid plaques in Alzheimer’s disease (AD) brains (Kudo et al. in J Nucl Med 8:553–561, 2007). We applied this tracer to subjects with mild cognitive impairment (MCI) and AD in order to elucidate the status of amyloid plaque deposition in MCI and compared the diagnostic performance of BF-227-PET with that of FDG–PET in AD cases. We studied 12 aged normal (AN) subjects, 15 MCIs and 15 ADs with PET using [11C]BF-227. PET images were obtained after administration of BF-227 and the regional standardized uptake value (SUV) and the ratio of regional to cerebellar SUV were calculated as an index of BF-227 binding. AD patients showed increased uptake of [11C]BF-227 in the neocortical areas and striatum as well as decreased glucose metabolism in temporoparietal, posterior cingulate and medial temporal areas. MCI subjects showed a significant increase in BF-227 uptake in the neocortical areas similar to AD, and the most significant difference of BF-227 retention was observed in the parietal lobe if its retentions for MCI were compared to those for AD and AN. On the other hand, glucose hypometabolism in MCI was confined to cingulate and medial temporal cortices. Neocortical BF-227 uptake negatively correlated with glucose metabolism. Receiver operating characteristic (ROC) analysis indicated higher specificity and sensitivity with BF-227-PET than those with FDG–PET for differential diagnosis between AD and normal control. We conclude that [11C]BF-227-PET has a possibility to be a useful technology for early detection of AD pathology and also even in the MCI stage.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Bennett DA, Cochran EJ, Saper CB, Leverenz JB, Gilley DW, Wilson RS (1993) Pathological changes in frontal cortex from biopsy to autopsy in Alzheimer’s disease. Neurobiol Aging 14:589–596

    Article  CAS  PubMed  Google Scholar 

  2. Chételat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC (2003) Mild cognitive impairment: Can FDG-PET predict who is to rapidly convert to Alzheimer’s disease? Neurology 60:1374–1377

    PubMed  Google Scholar 

  3. Chételat G, Eustache F, Viader F, De La Sayette V, Pélerin A, Mézenge F, Hannequin D, Dupuy B, Baron JC, Desgranges B (2005) FDG–PET measurement is more accurate than neuropsychological assessments to predict global cognitive deterioration in patients with mild cognitive impairment. Neurocase 11:14–25

    Article  PubMed  Google Scholar 

  4. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, Tsui W, Kandil E, Scherer AJ, Roche A, Imossi A, Thorn E, Bobinski M, Caraos C, Lesbre P, Schlyer D, Poirier J, Reisberg B (2001) Fowler et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/positron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 98:10966–10971

    Article  PubMed  Google Scholar 

  5. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A (2003) Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer’s disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 30:1104–1113

    Article  PubMed  Google Scholar 

  6. Forsberg A, Engler H, Almkvist O, Blomquist G, Hagman G, Wall A, Ringheim A, Långström B, Nordberg A (2008) A PET imaging of amyloid deposition in patients with mild cognitive impairment. Neurobiol Aging 29:1456–1465

    Article  CAS  PubMed  Google Scholar 

  7. Gómez-Isla T, Price JL, McKeel DW Jr, Morris JC, Growdon JH, Hyman BT (1996) Profound loss of layer II entorhinal cortex neurons occurs in very mild Alzheimer’s disease. J Neurosci 16:4491–4500

    PubMed  Google Scholar 

  8. Hardy J, Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297:353–356

    Article  CAS  PubMed  Google Scholar 

  9. Herholz K, Carter SF, Jones M (2007) PET studies in dementia. Br J Radiol 80:S160–S167

    Article  PubMed  Google Scholar 

  10. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: evidence that an initially deposited species is A beta 42(43). Neuron 13:45–53

    Article  CAS  PubMed  Google Scholar 

  11. Jicha GA, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol 63:674–681

    Article  PubMed  Google Scholar 

  12. Kemppainen NM, Aalto S, Wilson IA, Någren K, Helin S, Brück A, Oikonen V, Kailajärvi M, Scheinin M, Viitanen M, Parkkola R, Rinne JO (2007) PET amyloid ligand [11C]PIB uptake is increased in mild cognitive impairment. Neurology 68:1603–1606

    Article  CAS  PubMed  Google Scholar 

  13. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, Holt DP, Bergström M, Savitcheva I, Huang GF, Estrada S, Ausén B, Debnath ML, Barletta J, Price JC, Sandell J, Lopresti BJ, Wall A, Koivisto P, Antoni G, Mathis CA, Långström B (2004) Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B. Ann Neurol 55:306–319

    Article  CAS  PubMed  Google Scholar 

  14. Kudo Y, Okamura N, Furumoto S, Tashiro M, Furukawa K, Maruyama M, Itoh M, Iwata R, Yanai K, Arai H (2007) 2-(2-[2-Dimethylaminothiazol-5-yl]ethenyl) -6-(2-[fluoro]ethoxy)benzoxazole: a novel PET agent for in vivo detection of dense amyloid plaques in Alzheimer’s disease patients. J Nucl Med 8:553–561

    Google Scholar 

  15. Mathis CA, Klunk WE, Price JC, DeKosky ST (2005) Imaging technology for neurodegenerative diseases: progress toward detection of specific pathologies. Arch Neurol 62:196–200

    Article  PubMed  Google Scholar 

  16. Matsuda H (2007) Role of neuroimaging in Alzheimer’s disease, with emphasis on brain perfusion SPECT. J Nucl Med 48:1289–1300

    Article  PubMed  Google Scholar 

  17. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 34:939–944

    CAS  PubMed  Google Scholar 

  18. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE (1997) Metabolic reduction in the posterior cingulate cortex in very early Alzheimer’s disease. Ann Neurol 42:85–94

    Article  CAS  PubMed  Google Scholar 

  19. Okamura N, Arai H, Higuchi M, Tashiro M, Matsui T, Hu XS, Takeda A, Itoh M, Sasaki H (2001) [18F]FDG–PET study in dementia with Lewy bodies and Alzheimer’s disease. Prog Neuropsychopharmacol Biol Psychiatry 25:447–456

    Article  CAS  PubMed  Google Scholar 

  20. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308

    Article  CAS  PubMed  Google Scholar 

  21. Petersen RC (2004) Mild cognitive impairment as a diagnostic entity. J Intern Med 256:183–194

    Article  CAS  PubMed  Google Scholar 

  22. Petersen RC, Parisi JE, Dickson DW, Johnson K, Cha R, Ivnik RJ, Tangalos EG, Boeve BF, Knopman DS, Braak H, Petersen RC (2006) Neuropathologic features of amnestic mild cognitive impairment. Arch Neurol 63:665–672

    Article  PubMed  Google Scholar 

  23. Price JL, Morris JC (1999) Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease. Ann Neurol 45:358–368

    Article  CAS  PubMed  Google Scholar 

  24. Small GW, Kepe V, Ercoli LM, Siddarth P, Bookheimer SY, Miller KJ, Lavretsky H, Burggren AC, Cole GM, Vinters HV, Thompson PM, Huang SC, Satyamurthy N, Phelps ME, Barrio JR (2006) PET of brain amyloid and tau in mild cognitive impairment. N Engl J Med 355:2652–2663

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

This study was supported by the Program for the Promotion of Fundamental Studies in Health Science by the National Institute of Biomedical Innovation, the Special Coordination Funds for Promoting Science and Technology, the Industrial Technology Research Grant Program from the New Energy and Industrial Technology Development Organization of Japan, Health and Labour Sciences Research Grants for Translational Research from the Ministry of Health, and the Ministry of Education, Culture, Sports and Technology. We appreciate technical assistance of Dr. Shoichi Watanuki and Dr. Yoichi Ishikawa in the clinical PET studies and Dr. Motohisa Kato in the imaging analysis.

Author information

Authors and Affiliations

  1. Department of Geriatrics and Gerontology, Division of Brain Sciences, Institute of Development, Aging and Cancer, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8498, Japan

    Katsutoshi Furukawa, Masaaki Waragai & Hiroyuki Arai

  2. Department of Pharmacology, Tohoku University Graduate School of Medicine, 4-1 Seiryomachi, Aobaku, Sendai, 980-8575, Japan

    Nobuyuki Okamura, Shozo Furumoto & Kazuhiko Yanai

  3. Division of Cyclotron Nuclear Medicine, Cyclotron and Radioisotope Center, 6-3Aoba, Aramaki, Aoba-ku, Sendai, Miyagi, 980-8578, Japan

    Manabu Tashiro

  4. Division of Radiopharmaceutical Chemistry, Cyclotron and Radioisotope Center, 6-3Aoba, Aramaki, Aoba-ku, Sendai, Miyagi, 980-8578, Japan

    Ren Iwata

  5. Department of NeuroImaging Research, Innovation New Biomedical Engineering Center, Tohoku University, 4-1 Seiryomachi, Aobaku, Sendai, 980-8498, Japan

    Yukitsuka Kudo

Authors
  1. Katsutoshi Furukawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nobuyuki Okamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Manabu Tashiro
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Masaaki Waragai
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shozo Furumoto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ren Iwata
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Kazuhiko Yanai
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Yukitsuka Kudo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Hiroyuki Arai
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Katsutoshi Furukawa.

Additional information

K. Furukawa and N. Okamura equally contributed to the article.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Furukawa, K., Okamura, N., Tashiro, M. et al. Amyloid PET in mild cognitive impairment and Alzheimer’s disease with BF-227: comparison to FDG–PET. J Neurol 257, 721–727 (2010). https://doi.org/10.1007/s00415-009-5396-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-009-5396-8

Keywords

Search

Navigation